Embria Studies FDA Expectations Before Successful EpiCor NDI
This article was originally published in The Tan Sheet
FDA’s formal acknowledgment of Embria’s NDI notification for EpiCor comes after the firm called FDA early in the process to discuss the pending notification and worked to understand the agency’s expectations fully. Kevin Boot, Embria’s regulatory counsel, recommends simple notifications that are “readable by everyone.”
You may also be interested in...
OMB approves FDA’s estimate as the official measure for the supplement industry’s anticipated burden in complying with the NDI notification regulation.
Dr. Reddy’s launches Allegra-D equivalent
Supplement firms already should have compiled the information for a new dietary ingredient notification when they substantiated the safety of the ingredient, FDA says.